Tonix Pharmaceuticals Holding Corp (TNXP) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Tonix Pharmaceuticals Holding's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Tonix Pharmaceuticals Holding's ROI in the second quarter of 2026?
Tonix Pharmaceuticals Holding Corp recorded a cumulative net loss of $-160 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -68.72%.
Within the Healthcare sector 14 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3692 to 3775.
Advancements in Migraine Management: Tonix Pharmaceuticals Comprehensive Approach through Technology, Education, and Drug DevelopmentMigraine is a debilitating neurological disorder that affects millions of individuals worldwide. With its complex etiology and varied manifestations, the need for innovative solutions to enhance patient management is more crucial than ever. Tonix Pharmaceuticals the forefront of addressing these challenges has recently unveiled significant advancements to aid migraine sufferers through an integrated digital platform and the development of new therapies. This article delves into Tonix s launch of the TONIX ONE digital platform, its FDA New Drug Application for TNX-102 SL in fibromyalgia, and an awareness campaign highlighting the implications of gastroparesis on migraine medication absorption. Promoting Patient Empowerment: of the TONIX ONE Digital Platform Tonix Pharmaceuticals has launched the TONIX ONE, a fully integrated digital platform aimed at helping patients better understand and manage their migraine conditions. This platform addresses a fundamental aspect of migraine care: patient education and self-management. By partnering with the leading migraine diary app, Tonix enhances the accessibility and usability of real-time data, enabling patients to track their symptoms effectively, identify triggers, and engage in a community centered on shared experiences and knowledge.
In a strategic move aimed at bolstering its market presence, Tonix Pharmaceuticals Holding Corp has announced the appointment of Gary Ainsworth as Vice President of Market Access. Mr. Ainsworth, with over two decades of industry experience, is expected to strengthen the company s commercial leadership team and enhance its strategies in navigating the complexities of market access—a critical facet for biopharmaceutical success.This leadership transition arrives at a pivotal moment for Tonix Pharmaceuticals. Over the past 90 days, the company s share price has experienced a significant uptick of 154.54%. This surge reflects a growing investor interest and optimism surrounding the company’s prospects, particularly with the introduction of fresh leadership that brings extensive market access expertise to the table.
In an era defined by rapid advancements in biopharmaceuticals, Tonix Pharmaceuticals is emerging as a pivotal player in addressing urgent public health threats, particularly in the realm of infectious diseases. Recently, the company bolstered its leadership team with the strategic appointment of two executives, each bringing decades of expertise in launching and commercializing central nervous system (CNS) products. This is a significant move that underscores Tonix’s commitment to enhancing its operational capacity and strategic direction as it navigates a complex healthcare landscape.One of the foremost public health challenges that has captured global attention is the Mpox outbreak, which has been classified by the World Health Organization (WHO) as a public health emergency of international concern (PHEIC). In response to this urgent situation, Tonix Pharmaceuticals has made substantial progress in vaccine development, particularly with its promising candidate, TNX-801. This innovative vaccine is a single-dose live attenuated virus, designed to target both Mpox and smallpox. Recent findings published in the peer-reviewed journal mSphere have highlighted the vaccine s efficacy, demonstrating strong potential in immune-compromised animal models. These developments reflect not only Tonix’s dedication to addressing infectious diseases but also its responsive strategy against emerging health threats that challenge global health security.
Financial Statements
Tonix Pharmaceuticals Holding's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
